Signal transduction inhibitors of allergic reactions
US6084063A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Feb 6, 1998 |
| Grant date | Jul 4, 2000 |
| Priority date | — |
| Expiry date | Feb 6, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides an isolated polypeptide consisting of amino acids 1-66 of the human tyrosine kinase, Lyn A, in a pharmaceutically acceptable carrier and an isolated polypeptide consisting of amino acids 1-45 of the human tyrosine kinase, Lyn B, in a pharmaceutically acceptable carrier. The present invention also provides isolated nucleic acids encoding the above-described amino acid sequences, as well as vectors comprising the nucleic acids and cells comprising the vectors. The present invention further provides a method of treating or preventing an allergic disorder in a subject, comprising administering any of the above nucleic acids to a cell of the subject under conditions whereby the nucleic acid is expressed in the subject's cells, thereby treating the allergic disorder. Additionally provided in this invention is a fusion protein comprising either a polypeptide consisting of amino acids 1-66 of the human tyrosine kinase, Lyn A or a polypeptide consisting of amino acids 1-45 of the human tyrosine kinase, Lyn B and a ligand which binds to and is internalized by cells which express a high affinity receptor for IgE on the surface. A method of treating or preventing…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.